VivoSeq
Oncology

Lymphoplasmacytic Lymphoma

8

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Lymphoplasmacytic Lymphoma is an early-stage landscape with 8 programs across 7 companies. The most active players are AbbVie, Genzyme, a Sanofi Company, BeOne Medicines. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

11/100

Mech. Concentration

29/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2B

BeOne Medicines

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

6 of 9 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody222%Vaccine111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Completed2 · 40%

Clinical Trials

Trial Activity

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma
Completed·—·Phase 3·NCT00608374·400 enrolled
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Recruiting·AbbVie logoAbbVie·Phase 2·NCT07387471·14 enrolled
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07231952·40 enrolled
A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04840602·92 enrolled
Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma With DNA Vaccines Encoding Antigen-Chemokine Fusion
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01209871·9 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)